The HER2 subtype in this study accounted for 8.6% of all breast cancer cases, which is similar to that reported in Algeria (8.9%), but lower than in other North African countries (9.2–14.5%), and China (13.7%) (Table 3) [45, 60, 62, 65, 79, 80]. Here, ERBB2 is linked to breast carcinoma.